Spero (SPRO): Wutah pendapatan kuartal marang kuartal

Logo korporat perusahaan Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics (SPRO) develops innovative antibacterial agents to combat severe infections in the US. Diversified R&D and partnerships with industry behemoths mitigate risks, while stable capital ensures resilience until regulatory approval. The quarterly revenue growth rate on GURU.Markets illustrates the market reaction, where the value of -100.00 serves as a baseline indicator of current efficiency.

SPRO Wutah dodolan kuartal marang kuartal Spero (04.07.2022 - 20.11.2026)

Rincian metrik lan analitis perusahaan Spero Therapeutics Inc (SPRO)

- rega saham lan target rega konsensus:
Ringkesan analisis perusahaan:Spero Therapeutics Inc (SPRO)
Produk seri Spero Therapeutics, Inc.

Antibiotic development at Spero Therapeutics (SPRO) requires significant expenditures for the environmentally safe disposal of chemicals, which directly impacts operating margins. By analyzing the quarterly sales growth chart, an investor assesses revenue inflow dynamics relative to the previous period, identifying hidden costs and business scaling trends, which helps avoid capital losses amid changes in regulatory policy.